Clinical Trial Update: Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating intralesional cemiplimab in adults with early-stage cutaneous squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 3 | Status: RECRUITING